LEADER 05322nam 22006494a 450 001 9910144698803321 005 20170919210923.0 010 $a1-282-35017-X 010 $a9786612350177 010 $a0-470-98579-8 010 $a0-470-98578-X 035 $a(CKB)1000000000687511 035 $a(EBL)470159 035 $a(OCoLC)609848740 035 $a(SSID)ssj0000312772 035 $a(PQKBManifestationID)11223169 035 $a(PQKBTitleCode)TC0000312772 035 $a(PQKBWorkID)10332302 035 $a(PQKB)10941282 035 $a(MiAaPQ)EBC470159 035 $a(PPN)199221944 035 $a(EXLCZ)991000000000687511 100 $a20071207d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aViral therapy of cancer$b[electronic resource] /$feditors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha 210 $aChichester, England ;$aHoboken, NJ $cJohn Wiley & Sons$dc2008 215 $a1 online resource (426 p.) 300 $aDescription based upon print version of record. 311 $a0-470-01922-0 320 $aIncludes bibliographical references and index. 327 $aViral Therapy of Cancer; Contents; Foreword; Preface; Contributors; 1 Adenoviruses; 1.1 Introduction; 1.2 Viral structure and life cycle; 1.3 Adenoviral vectors; 1.4 Targeting adenoviral vectors; 1.5 Clinical applications of adenoviral gene therapy; 1.6 Adenoviral vectors for immunotherapy; 1.7 Adenoviral vectors for suicide gene therapy; 1.8 Adenoviral vectors for gene replacement therapy; 1.9 Oncolytic adenoviral therapy; 1.10 Adverse outcomes of adenoviral gene therapy; 1.11 Summary; References; 2 Application of HSV-1 vectors to the treatment of cancer; 2.1 Introduction 327 $a2.2 Basic biology of HSV2.3 Replication competent or oncolytic vectors; 2.4 Replication defective vectors; 2.5 Amplicons; 2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy; 2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy; 2.8 Summary and conclusions; Acknowledgements; References; 3 Adeno-associated virus; 3.1 Introduction; 3.2 Biology and life cycle of AAV; 3.3 AAV serotypes; 3.4 Production of recombinant AAV; 3.5 Gene therapy for cancer treatment; 3.6 Anti-oncogenic properties of AAV 327 $a3.7 Molecular chemotherapy studies with rAAV3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy; 3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses; 3.10 rAAV vectors can be used to initiate immune responses; 3.11 Altering AAV tropism for tumour-specific delivery; 3.12 Clinical trials involving rAAV; 3.13 Conclusion; Acknowledgements; References; 4 Retroviruses; 4.1 Introduction; 4.2 Structure of retroviral particles; 4.3 Retroviral genome; 4.4 Retroviral life cycle; 4.5 Retroviral vectors 327 $a4.6 Safety of retroviral vectors: insertional mutagenesis4.7 Gene therapy of X-linked SCID; 4.8 Retroviral cancer gene therapy; 4.9 Immunomodulatory approaches; 4.10 Conclusions; References; 5 Lentiviral vectors for cancer gene therapy; 5.1 Development of lentiviral vectors (LV); 5.2 Targeting of transgene expression; 5.3 Host immune responses to LV and their transgene; 5.4 Transgenesis; 5.5 Haematopoietic stem cell gene transfer; 5.6 Cancer treatment by LV; 5.7 Approved clinical trials using LV; 5.8 Conclusions; References; 6 Poxviruses as immunomodulatory cancer therapeutics 327 $a6.1 Introduction6.2 General features of poxvirus structure and biology; 6.3 Clinically applicable poxviruses; 6.4 Poxviruses as potential cancer therapeutics; 6.5 Clinical experience with poxviruses; 6.6 Conclusions; References; 7 Oncolytic herpes simplex viruses; 7.1 Introduction; 7.2 Herpes simplex virology; 7.3 Properties of HSV relevant to oncolytic virus therapy; 7.4 Mutations giving tumour-selective replication; 7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG); 7.6 Prodrug activation therapy and oncolytic HSV 327 $a7.7 Combination of oncolytic HSV with immunomodulatory gene expression 330 $aIn the last decade there has been an explosion of interest in viral therapies for cancer. Viral agents have been developed that are harmless to normal tissues but selectively able to kill cancer cells. These agents have been endowed with additional selectivity and potency through genetic manipulation. Increasingly these viruses are undergoing evaluation in clinical trials, both as single agents and in combination with standard chemotherapy and radiotherapy. This book provides a comprehensive yet succinct overview of the current status of viral therapy of cancer. Chapters coherently present 606 $aViruses$xTherapeutic use 606 $aCancer$xTreatment 615 0$aViruses$xTherapeutic use. 615 0$aCancer$xTreatment. 676 $a616.99/406 676 $a616.99406 701 $aHarrington$b Kevin J.$f1958-$038288 701 $aPandha$b Hardev$0949550 701 $aVile$b Richard G$078071 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144698803321 996 $aViral therapy of cancer$92146250 997 $aUNINA